Rare Disease Clinical Trials Market Revenue Expected to Reach $19.44 Billion by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 How Has the Rare Disease Clinical Trials Market Evolved in Terms of Size and Value From 2025 to 2029?
 The rare disease clinical trials market size has grown rapidly in recent years. It will grow from $12.06 billion in 2024 to $13.30 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising awareness of genetic disorders among healthcare providers, increasing demand for specialized patient monitoring during trials, rising development of personalized medicine approaches, growing adoption of patient-centric trial methodologies, and growing need for global multi-center clinical studies.
 
 The rare disease clinical trials market size is expected to see rapid growth in the next few years. It will grow to $19.45 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to the rise in the number of rare disease therapies entering clinical trials, the increase in regulatory support for orphan drug approvals, the increase in disease-specific patient registries and databases, the rise in cross-border clinical trials and multi-center studies, and the increase in funding initiatives for rare disease research infrastructure. Major trends in the forecast period include advanced use of decentralized trial models, innovation in patient recruitment strategies, integration of real-world evidence in trial designs, development of precision medicine approaches, and increasing adoption of digital health technologies.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28311&type=smp
  
 Which Key Drivers Are Fueling Growth in the Rare Disease Clinical Trials Market?
 The rise of personalized medicine is expected to propel the growth of the rare disease clinical trials market going forward. Personalized medicine refers to tailoring medical treatment to the individual characteristics of each patient, such as genetics, lifestyle, and environment. The increase in personalized medicine is due to the improved treatment outcomes, as it tailors therapies to individual patient profiles for greater efficacy and safety. Rare disease clinical trials advance personalized medicine by generating patient-specific insights that guide the development of targeted therapies tailored to each individual’s unique genetic and molecular profile. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the Food and Drug Administration (FDA) reported that personalized medicines represented 34% of approvals in 2022, which further increased to 38% in 2023. Therefore, the rise of personalized medicine is driving the growth of the rare disease clinical trials market.
 
 What Are the Major Segments Defining the Structure of the Rare Disease Clinical Trials Market?
 The rare disease clinical trials market covered in this report is segmented as
 
 1) By Phase: Phase I, Phase II, Phase III, Phase IV
 2) By Therapeutic Area: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune And Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas
 3) By Study Design: Interventional, Observational, Expanded Access
 4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End-Users
 
 Subsegments:
 1) By Phase I: First In Human Trials, Dose Escalation Studies, Safety And Tolerability Studies
 2) By Phase II: Proof Of Concept Studies, Dose Response Studies, Efficacy And Safety Studies
 3) By Phase III: Randomized Controlled Trials, Comparative Effectiveness Studies, Large Scale Multicenter Trials
 4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies
 
 What New Market Trends Are Emerging in the Rare Disease Clinical Trials Market?
 Major companies operating in the rare disease clinical trials market are focusing on driving innovations, such as adopting a client-centric approach to deliver personalized trial designs, enhancing patient engagement, and accelerating the development of targeted therapies for rare conditions. A client-centric approach refers to prioritizing the needs, goals, and preferences of biotech and pharmaceutical clients to provide tailored and effective clinical trial solutions. For instance, in March 2025, Evestia Clinical Limited, a US-based pharmaceutical research company, was introduced as the new brand identity of EMAS Pharma. The rebranding represents a strategic move to accelerate the company’s global expansion. The company is committed to accelerating the development of therapies for rare diseases by providing expert-driven, personalized clinical trial solutions tailored to the unique challenges of these conditions. This focus is a key part of its brand identity and service offering.
 
 Which Key Players Dominate the Rare Disease Clinical Trials Market Landscape?
 Major companies operating in the rare disease clinical trials market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, Moderna Inc., Charles River Laboratories International Inc., Parexel International Corporation, Revvity Inc., Sarepta Therapeutics Inc., TFS HealthScience, Inventiva S.A., Tonix Pharmaceuticals Holding Corp., SpringWorks Therapeutics Inc., OrphAI Therapeutics Inc., BBCR Consulting LLC, and Credevo Inc.
 
 Get the detailed rare disease clinical trials market report today
 https://www.thebusinessresearchcompany.com/report/rare-disease-clinical-trials-global-market-report
 
 Which Region Is Expected to Dominate the Rare Disease Clinical Trials Market During the Forecast Period?
 North America was the largest region in the rare disease clinical trials market in 2024. The regions covered in rare disease clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company